Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis

Area of Science:

• Neurology
• Neuroimmunology
• Biochemistry

Background:

• Multiple sclerosis (MS) presents with distinct clinical courses, primarily relapsing-remitting (RRMS) and secondary progressive (SPMS).
• Differentiating between RRMS and SPMS is crucial for appropriate treatment strategies and prognosis.
• Cerebrospinal fluid (CSF) analysis offers potential biomarkers for disease characterization.

Purpose of the Study:

• To investigate the utility of CSF analysis in differentiating between RRMS and SPMS.
• To identify specific CSF parameters that can serve as biomarkers for MS disease progression.

Main Methods:

• Analyzed CSF from 17 RRMS and 16 SPMS patients for various biochemical and cellular markers.
• Included albumin CSF/PB ratio, mononuclear cells (MNCs) and subsets, immunoglobulins (IgG, IgM), complement components (C3, C4), myelin basic protein, neuron-specific enolase (NSE), S100, and lactate.
• Employed linear discriminant analysis to develop a composite CSF score using statistically significant variables (P ≤ 0.15).

Main Results:

• A discriminant score incorporating albumin CSF/PB ratio, MNC number, IgM, IgM index, C3, C4, NSE, S100, and lactate effectively differentiated between RRMS and SPMS patients.
• The developed score correctly classified 100% of RRMS patients and 93.75% of SPMS patients.
• Significant differences in CSF profiles were observed between RRMS and SPMS groups.

Conclusions:

• CSF analysis reveals distinct profiles between RRMS and SPMS.
• A composite CSF score derived from specific biomarkers can accurately differentiate between RRMS and SPMS in individual patients.
• This finding supports the use of CSF analysis as a diagnostic tool for MS subtype classification.